Dapagliflozin granted Fast Track designation in the US for reduction of risk of hospitalisation for heart failure or cardiovascular death following acute myocardial infarction

The designation is based on the Phase III DAPA-MI placebo controlled trial that will explore the safety and efficacy of dapagliflozin in patients without type 2 diabetes following an acute MI. It is expected to begin recruiting later in 2020.


Biospace Inc.